BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 18665834)

  • 1. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
    Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
    Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
    [No Abstract]   [Full Text] [Related]  

  • 2. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
    Marcucci G; Perrotti D; Caligiuri MA
    Clin Cancer Res; 2003 Apr; 9(4):1248-52. PubMed ID: 12684391
    [No Abstract]   [Full Text] [Related]  

  • 4. [Second hematologic response and disappearance of the ABL gene mutant clone by cessation of imatinib in a CML patient with resistance to imatinib].
    Murase K; Matsunaga T; Takeuchi N; Fujimi A; Takimoto R; Terui T; Hirayama Y; Niitsu Y
    Rinsho Ketsueki; 2004 Sep; 45(9):1028-32. PubMed ID: 15510830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
    Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
    Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
    Moser AM; Manor E; Narkis G; Kapelushnik J
    Cancer Genet Cytogenet; 2006 Oct; 170(1):54-7. PubMed ID: 16965955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.
    Roche-Lestienne C; Laï JL; Darré S; Facon T; Preudhomme C
    N Engl J Med; 2003 May; 348(22):2265-6. PubMed ID: 12773665
    [No Abstract]   [Full Text] [Related]  

  • 8. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment.
    Breccia M; Muscaritoli M; Cannella L; Loglisci G; Santopietro M; Alimena G
    Leuk Res; 2010 May; 34(5):e122-4. PubMed ID: 20018374
    [No Abstract]   [Full Text] [Related]  

  • 10. Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients.
    Szych CM; Liesveld JL; Iqbal MA; Li L; Siebert S; Asmus C; O'Malley J; Lee A; Wang N
    Cancer Genet Cytogenet; 2007 Apr; 174(2):132-7. PubMed ID: 17452255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
    Espinet B; Oliveira AC; Boqué C; Domingo A; Alonso E; Solé F
    Haematologica; 2005 Apr; 90(4):556-8. PubMed ID: 15820956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [STI571: the resistance organizes!].
    Jeanteur P
    Bull Cancer; 2001 Sep; 88(9):819. PubMed ID: 11642306
    [No Abstract]   [Full Text] [Related]  

  • 13. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Drummond MW; Holyoake TL
    Cancer; 2003 Oct; 98(8):1776-7; author reply 1777-8. PubMed ID: 14534900
    [No Abstract]   [Full Text] [Related]  

  • 14. A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients.
    Curvo RP; Zalcberg IR; Scholl V; Pires V; Moellmann-Coelho A; Moreira MA
    Leuk Res; 2008 Mar; 32(3):508-10. PubMed ID: 17570524
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia.
    Park TS; Cheong JW; Kim SJ; Lee KW; Song J; Lee KA; Suh B; Song S; Choi JR
    Cancer Genet Cytogenet; 2009 Apr; 190(1):46-8. PubMed ID: 19264234
    [No Abstract]   [Full Text] [Related]  

  • 17. CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports.
    Abruzzese E; Cantonetti M; Morino L; Orlandi G; Tendas A; Del Principe MI; Masi M; Amadori S; Orlandi A; Anemona L; Campione E
    J Clin Oncol; 2003 Nov; 21(22):4256-8. PubMed ID: 14615464
    [No Abstract]   [Full Text] [Related]  

  • 18. Resistance to imatinib mesylate in chronic myeloid leukaemia.
    Melo JV; Chuah C
    Cancer Lett; 2007 May; 249(2):121-32. PubMed ID: 16949736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
    Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
    [No Abstract]   [Full Text] [Related]  

  • 20. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
    Kantarjian H; O'Brien S; Talpaz M; Borthakur G; Ravandi F; Faderl S; Verstovsek S; Rios MB; Shan J; Giles F; Cortes J
    Cancer; 2007 Apr; 109(8):1556-60. PubMed ID: 17342766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.